2型糖尿病口服降糖药药物基因组学研究进展

发布时间：2018-11-03 06:58

【摘要】：T2DM是一种常见的慢性代谢疾病,其病因复杂,由环境因素和遗传因素共同作用引起。目前,治疗T2DM的口服降糖药主要有双胍类,磺脲类,TZDs,氯茴苯酸类等几大类。已经确定一些基因与T2DM的发展和治疗效果有关。人类基因组中个体间的差异会影响T2DM发展趋势和同一药物疗法的个性化反应。药物基因组学研究的重点是基因单核苷酸多态性及其对药物疗效和毒性的个性化反应的影响。T2DM的药物基因组学研究对于精准医学以及个性化用药的应用具有重要的意义,改善糖尿病治疗效果。本文对糖尿病治疗药物及其相关的基因多态性信息进行综述。
[Abstract]:T2DM is a common chronic metabolic disease, its etiology is complex, caused by environmental factors and genetic factors. At present, the main oral hypoglycemic drugs for T2DM include biguanidine, sulfonylurea, TZDs, chloranisole and so on. Some genes have been identified to be relevant to the development and therapeutic effects of T2DM. Individual differences in the human genome can influence the development trend of T2DM and the individualized response of the same drug therapy. The focus of pharmacogenomics is the single nucleotide polymorphism of gene and its influence on the individualized reaction of drug efficacy and toxicity. The pharmacogenomics research of T2DM is of great significance for the application of precision medicine and individualized medicine. To improve the effect of diabetes treatment. This article reviews the information of diabetes treatment drugs and related gene polymorphisms.
【作者单位】：北京市科学技术研究院北京市计算中心北京市基因测序与功能分析工程技术中心云计算关键技术与应用北京市重点实验室;
【基金】：北京市科学技术研究院创新团队项目(IG201406C2) 北京市委组织部优秀人才青年骨干项目(2015400685627G238)
【分类号】：R587.1

【相似文献】